VRTX VERTEX PHARMACEUTICALS INC Investments/Divestments 8-K Filing 2023 - FDA Approval and Pricing Announcement The U.S. FDA approved CASGEVY gene therapy for sickle cell disease with a wholesale acquisition cost of $2.2 million.Get access to all SEC 8-K filings of the VERTEX PHARMACEUTICALS INC